SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotech company pioneering a new era of G protein-coupled receptor (GPCR) drug...
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Septerna, a clinical-stage biotechnology company pioneering a new era of GPCR-targeted drug discovery, today announced that Jeffrey...
Deep Pipeline of GPCR Programs Focused Initially on Indications in Endocrinology, Immunology and Inflammation, and Metabolic Diseases Phase 1 Clinical Trial Ongoing for SEP-786, Oral Small...
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR...
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -3.54 | -17.3274596182 | 20.43 | 20.55 | 15.86 | 224125 | 17.16476324 | CS |
4 | -6.665 | -28.2954786669 | 23.555 | 28.99 | 15.86 | 429697 | 23.05313966 | CS |
12 | -6.61 | -28.1276595745 | 23.5 | 28.99 | 15.86 | 323622 | 23.0355656 | CS |
26 | -6.61 | -28.1276595745 | 23.5 | 28.99 | 15.86 | 323622 | 23.0355656 | CS |
52 | -6.61 | -28.1276595745 | 23.5 | 28.99 | 15.86 | 323622 | 23.0355656 | CS |
156 | -6.61 | -28.1276595745 | 23.5 | 28.99 | 15.86 | 323622 | 23.0355656 | CS |
260 | -6.61 | -28.1276595745 | 23.5 | 28.99 | 15.86 | 323622 | 23.0355656 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.